Acute Leukemia | Medscape Acute Leukemia | Medscape
Acute forms of leukemia include acute myeloid leukemia and acute lymphoblastic leukemia, also known as lymphoblastic lymphoma. (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 3, 2019 Category: Consumer Health News Tags: Resource Center Source Type: news
Aspergillus nidulans appendicitis in a paediatric patient with acute myeloid leukaemia
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - July 1, 2019 Category: Respiratory Medicine Authors: pChrisopoulos Source Type: news
Woman with leukemia survives risky half-matched marrow transplant
Kyla Ubbelohde, now 27, was diagnosed with acute myeloid leukemia in 2017 and relapsed soon after. Her brother flew to Iowa to donate his marrow, but he was only a 50% match, making it risky. (Source: the Mail online | Health)
Source: the Mail online | Health - June 25, 2019 Category: Consumer Health News Source Type: news
Daiichi Sankyo Provides Update on FDA Review of Quizartinib for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
TOKYO and BASKING RIDGE, N.J., June 21, 2019 -- (Healthcare Sales & Marketing Network) -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the company received a Complete Response Letter (CRL) from the U.S. Food and Drug Ad... Biopharmaceuticals, Oncology, FDA Daiichi Sankyo, quizartinib, acute myeloid leukemia, FLT3 inhibitor (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 21, 2019 Category: Pharmaceuticals Source Type: news
High Response Seen for Chemo in Seniors With High-Risk AML
THURSDAY, June 20, 2019 -- A substantial proportion of older patients with high-risk acute myeloid leukemia (AML) treated with chemotherapy are long-term survivors, according to research published online June 7 in Cancer Medicine.
Sarah Bertoli,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 20, 2019 Category: Pharmaceuticals Source Type: news
UTSA Researchers Create Leukemia Proteome Atlases to Assist in Leukemia Research and Personalized Medicine Treatments
This new atlas of leukemia proteomes may prove useful for medical laboratories and pathologists providing diagnostic and prognostic services to physicians treating leukemia patients Clinical pathology laboratories, hematopathologists, and medical technologists (aka, medical laboratory scientists) have a new tool that aids in leukemia research and helps hematologists and other medical practitioners treat patients with acute […] (Source: Dark Daily)
Source: Dark Daily - June 19, 2019 Category: Laboratory Medicine Authors: Jude Tags: Digital Pathology Instruments & Equipment Laboratory Pathology Management & Operations News From Dark Daily acute myelogenous leukemia Amina Qutub PhD AML anatomic pathology clinical laboratory dark intelligence group Dark Report L Source Type: news
FDA warns that symptoms of a serious condition affecting the blood cells are not being recognized with the leukemia medicine Idhifa (enasidenib)
The U.S. Food and Drug Administration (FDA) is warning that signs and symptoms of a life-threatening side effect called differentiation syndrome are not being recognized in patients receiving the acute myeloid leukemia medicine Idhifa (enasidenib). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 18, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
CX-01 Heparin Derivative Investigated for Older Patients With AML
A randomized phase II trial investigated whether adding CX-01, a low anticoagulant heparin derivative, to standard care improves outcomes in older patients with acute myeloid leukemia. (Source: CancerNetwork)
Source: CancerNetwork - June 14, 2019 Category: Cancer & Oncology Authors: John Schieszer Source Type: news
Allo-HCT With Unrelated Donor Tied to Better Outcomes in AML
TUESDAY, June 4, 2019 -- Allogeneic hematopoietic cell transplantation (allo-HCT) with an unrelated donor (UD) results in better transplantation outcomes than cord blood transplantation (CBT) in acute myeloid leukemia (AML) patients with active... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 4, 2019 Category: Pharmaceuticals Source Type: news
Benefits With Gilteritinib for AML Were Maintained, Regardless of Co-Mutations
The survival benefit observed with gilteritinib in FLT3-mutated relapsed/refractory acute myeloid leukemia in the ADMIRAL trial was maintained regardless of the presence of several common co-mutations. (Source: CancerNetwork)
Source: CancerNetwork - June 4, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news
Jazz Pharmaceuticals Appoints Dr. Robert Iannone as Executive Vice President, Research and Development
DUBLIN, June 3, 2019 -- (Healthcare Sales & Marketing Network) -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the appointment of Robert Iannone, M.D., M.S.C.E., as executive vice president, research and development, effective May 29, 2019. Dr.... Biopharmaceuticals, Oncology, Personnel Jazz Pharmaceuticals, Vyxeos, acute myeloid leukemia, myelodysplasia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 3, 2019 Category: Pharmaceuticals Source Type: news
Largest Analysis to Date Examines Link Between Smoking and Outcomes in Acute Myeloid Leukemia
Data was presented at ASCO 2019 on the link between current and former smoking on treatment outcomes in AML in treatment-naïve patients. (Source: CancerNetwork)
Source: CancerNetwork - June 3, 2019 Category: Cancer & Oncology Authors: Jim Kling Source Type: news
U.S. FDA Approves Supplemental New Drug Application Adding Overall Survival Data for XOSPATA(R) (gilteritinib)
Phase 3 ADMIRAL trial showed patients treated with XOSPATA demonstrated longer Overall Survival than those who received salvage chemotherapy[1]
XOSPATA is the only FDA-approved targeted treatment for adult patients with relapsed or refractory FLT3 mutat... Biopharmaceuticals, Oncology, FDA Astellas Pharma, XOSPATA, gilteritinib, Acute Myeloid Leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 30, 2019 Category: Pharmaceuticals Source Type: news
Octogenarians With Acute Myeloid Leukemia Have Poor Survival
Overall survival 1.5 months; survival improved for those receiving chemotherapy (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 21, 2019 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Geriatrics, Journal, Source Type: news
Octogenarians With Acute Myeloid Leukemia Have Poor Survival
TUESDAY, May 21, 2019 -- Octogenarians with acute myeloid leukemia (AML) have a one-month mortality rate of 41 percent and overall survival (OS) of 1.5 months, according to a research letter published in the June issue of the American Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 21, 2019 Category: Pharmaceuticals Source Type: news
